H16 Arsenic to biologics: psoriasis treatment through the ages
نویسندگان
چکیده
Abstract In the 19th century when arsenic was recommended treatment for psoriasis, little consideration given to toxic side-effects of potent carcinogen. Thomas Girdlestone, an English physician, is said have been first advocate use treat psoriasis. Girdlestone prescribed Fowler’s solution, a solution potassium arsenite 1%. 1876, Alexander John Balmanno Squire inadvertently discovered dithranol, known ringworm, be efficacious in treating However, it Eugen Galewsky, 1916, who then went on synthesize anthralin, synthetic form target A key historical figure William H. Geockerman, American dermatologist, developed Goekerman therapy—a regimen that combined coal tar and ultraviolet (UV) light moderate-to-severe plaque 1953, Ingram, beneficial effects dithranol paste could enhanced by adding UV light—later coined ‘Ingram regimen’. Philip Showalter Hench, Edward Calvin Kendall Tadeus Reichstein received Nobel Prize Medicine Physiology development cortisone; proved useful topically many skin diseases, but had limited effect The production corticosteroids soon followed, which, conversely, successful daunting their long-term use. 1951, patient with rheumatoid arthritis showed dramatic improvement psoriasis treated aminopterin, as recorded Richard Gubner, New York cardiologist. PUVA 1970s—a photochemotherapy psoralen UVA radiation clear lesions. Interestingly, 1500 Bc, ancient Egyptians were combination sunlight vitiligo. Furthermore, 1980s, researchers noted complete clearance osteoporosis oral vitamin D. This chance observation led topical D analogues work encouraging normal growth slowing down overproduction cells. Finally, 2003, biologic treatments approved US Food Drug Administration—a significantly safer more alternative controversial used over 200 years ago.
منابع مشابه
Patient-Centered Approach to Biologics in the Treatment of Psoriasis
Background: With a growing number of psoriasis treatments options, making a decision can be daunting to patients. Biologics offer a less toxic and more effective alternative to people who have moderate-to-severe psoriasis, particularly those who have tried and failed other therapies. Objective: To provide a patient-centered approach to the decision to start on biologic treatment of psoriasis wi...
متن کاملBiologics in the management of psoriasis
Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and...
متن کاملBiologics for Psoriasis and Psoriatic Arthritis
The purposes of this updated review of antipsoriatic biologic agents are to compare their pharmacologic properties and evaluate studies that address certain key clinical questions that are pertinent to the development of criteria for use of biologic agents for chronic plaque psoriasis (CPP) and psoriatic arthritis (PsA) in the Veterans Health Administration. No studies involving a U.S. Veteran ...
متن کاملThe new biologics in psoriasis: possible treatments for alopecia areata.
Therapeutics in alopecia areata (AA) have remained relatively unchanged for many years, with few treatments having more than moderate effects in severely affected patients. The advent of the new biologic medications in the dermatologic world, however, particularly in psoriasis treatment, introduces possibilities of treatment for many other immune-mediated diseases.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Dermatology
سال: 2023
ISSN: ['1365-2133', '0007-0963']
DOI: https://doi.org/10.1093/bjd/ljad113.298